Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Summary

The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.

Timeline

Start

1996-11

Primary completion

—

Completion

2004-02

Outcome

Missed primary endpoint

paper This primary end point favored the dapsone-treated group but was not statistically significant (P = .37). PMID 18209165 ↗

Publications

• Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, Jacobus D. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008 Jan;144(1):25-32. doi: 10.1001/archderm.144.1.25.

Drugs

Indications